SCHEMBL711746

SCHEMBL711746

CC(C)(C)c1cc(N)n(C(C)(C)C)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
POLB P06746 1/20 0.38
HPGD P15428 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GRN P28799 2/20 0.36
SORT1 Q99523 2/20 0.36
HSD17B10 Q99714 1/20 0.33
CSF1R P07333 2/20 0.33
RET P07949 2/20 0.33
CSNK1A1 P48729 2/20 0.33
CDK8 P49336 2/20 0.33
CLK2 P49760 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
AURKA O14965 1/20 0.33
LTK P29376 1/20 0.33
CDK5 Q00535 1/20 0.33
ACVR1 Q04771 1/20 0.33
PLK4 O00444 1/20 0.31
RIPK2 O43353 1/20 0.31
ROCK2 O75116 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17045543 0.83 HSP90AA1 (0.37) KDM4EHPGDSMN1; SMN2ALDH1A1LMNA
SCHEMBL432964 0.76 KDM4E (0.50) KDM4EPOLBGRNSORT1HSD17B10
SCHEMBL12859083 0.76 NPC1 (0.39) KDM4EPOLBHPGDSMN1; SMN2GRN
SCHEMBL10156873 0.76 GRN (0.37) KDM4EPOLBGRNSORT1CSF1R
SCHEMBL399615 0.76 POLB (0.44) KDM4EPOLBHPGDSMN1; SMN2ALDH1A1
SCHEMBL21305805 0.74 GRN (0.40) KDM4EPOLBSMN1; SMN2GRNSORT1
SCHEMBL19433402 0.74 SMN1; SMN2 (0.38) KDM4EPOLBHPGDSMN1; SMN2RET
SCHEMBL15472828 0.71 CDK8 (0.51) KDM4ESMN1; SMN2GRNSORT1CSF1R
SCHEMBL12545850 0.71 GRN (0.34) KDM4EHPGDGRNSORT1LMNA
SCHEMBL3843249 0.71 KDM4E (0.46) KDM4EPOLBSMN1; SMN2GRNSORT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119490458-A C-3 pyrazole substituted indazole derivative and application thereof 沈阳药科大学 2025-02-21 CN disclosed
WO-2025035645-A1 C-3 PYRAZOLE SUBSTITUTED INDAZOLE DERIVATIVE AND USE THEREOF 沈阳药科大学 2025-02-20 WO disclosed
US-11560391-B2 Sulfonylurea compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2023-01-24 US disclosed
US-11560391-B2 Sulfonylurea compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2023-01-24 US disclosed
EP-3823726-A1 SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY F. Hoffmann-La Roche SA (CH) 2021-05-26 EP disclosed
CN-112437683-A Sulfonylurea compounds useful as inhibitors of interleukin-1 activity 豪夫迈·罗氏有限公司 2021-03-02 CN disclosed
WO-2020018970-A1 SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2020-01-23 WO disclosed
WO-2020018970-A1 SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2020-01-23 WO disclosed
US-9771353-B2 Kinase inhibitors based upon N-alkyl pyrazoles TOPIVERT PHARMA LIMITED (GB) 2017-09-26 US disclosed
EP-2981534-B1 KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES TOPIVERT PHARMA LTD (GB) 2017-07-19 EP disclosed
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-13 US disclosed
US-20070197624-A1 Acylated amino acid amidyl pyrazoles and related compounds ELAN PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-20070197624-A1 Acylated amino acid amidyl pyrazoles and related compounds ELAN PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-20070010548-A1 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof ZENTARIS GMBH (DE) 2007-01-11 US disclosed
US-20070010548-A1 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof ZENTARIS GMBH (DE) 2007-01-11 US disclosed
US-20070010548-A1 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof ZENTARIS GMBH (DE) 2007-01-11 US disclosed
EP-1648463-A2 COMPOUNDS HAVING INHIBITIVE ACTIVITY OF PHOSPHATIDYLINOSITOL 3-KINASE AND METHODS OF USE THEREOF Zentaris GmbH (DE) 2006-04-26 EP disclosed
EP-1633350-A2 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS Elan Pharmaceuticals, Inc. (US) 2006-03-15 EP disclosed
WO-2005016245-A2 COMPOUNDS HAVING INHIBITIVE ACTIVITY OF PHOSPHATIDYLINOSITOL 3-KINASE AND METHODS OF USE THEREOF ZENTARIS GMBH (DE) 2005-02-24 WO disclosed
WO-2005009344-A2 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197624-A1 Acylated amino acid amidyl pyrazoles and related compounds APP, BACE1, APH1A KDM4E 3673/4885POLB 4429/4885HPGD 1737/4885
US-11560391-B2 Sulfonylurea compounds as inhibitors of interleukin-1 activity IL1B, IL1A, IL18 KDM4E 4310/4885POLB 4762/4885HPGD 2797/4885
US-20070010548-A1 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof IPMK, PI4KB, PDPK1 KDM4E 2220/4885POLB 2356/4885HPGD 1340/4885
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds NR2E1, NR0B1, BRAF KDM4E 1292/4885POLB 765/4885HPGD 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.